ReviewEJNMMI reports2025
Emerging PET-radiotracers in cardiovascular, neuro-inflammation, lung and rheumatological diseases: a narrative review.
Review in EJNMMI reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Annals of nuclear medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImaging plays a crucial role in the clinical management of patients with inflammatory diseases, both for diagnosis and in evaluating treatment response. 2-deoxy-2-[18F]-fluoro-D-glucose ([
methodsThis narrative review aims to explore and discuss the emerging role of new PET/CT radiopharmaceuticals in the field of inflammation taking into account findings from recent studies in this setting.
resultsPreliminary promising findings are available in the literature regarding the potential usefulness of new radiotracers for investigating inflammatory diseases, especially in cardiovascular, neurological, rheumatological and pulmonary fields. In cardiovascular inflammation, different radiopharmaceuticals showed promising roles according to the disease evaluated, but globally the findings are preliminary and heterogeneous. Concerning cardiac sarcoidosis, somatostatin Receptor Subtype 2 (SSTR2)-ligands, translocator protein (TSPO) radiotracers, and hypoxic radiotracers were investigated but until now so strong evidence were available. About vasculitis, SSTR2-ligands and CXCR4 radiotracers showen the most promising findings, especially in the evaluation of treatment response. Regarding atherosclerosis and mycoarditis, we have positive preclinical studies but lack of evidence from a clinical point of view. For neuroinflammation, the available findings on new PET radiotracers are still limited even if TSPO PET seems the most promising due to the ability to image microglial activation. Instead, about lung and rheumatological inflammatory diseases, fibroblast activation protein inhibitors (FAPI) appear to be the most promising radiopharmaceutical, even better than [
conclusionsEmerging PET radiotracers showed promising results in detecting inflammatory diseases in different anatomical sites, but more robust and comprehensive studies are required for their clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.